natgillin/translations-raw huggingface dataset:
Azilect must not be used in patients who have severe problems with their liver. 
Prav tako ga ne smejo uporabljati bolniki s hudimi težavami z jetri.
Azilect was more effective than placebo in all of the studies. 
V vseh študijah je bilo zdravilo Azilect učinkovitejše od placeba.
In the study where Azilect was used alone, patients taking 1 mg of the medicine once a day had an average fall in UPDRS score of 0.13 points over the 26-week study from a starting value of 24.69. 
V študiji, v kateri je bilo zdravilo Azilect uporabljeno samostojno, je bilo pri bolnikih, ki so prejemali 1 mg zdravila enkrat dnevno, po 26-tedenski študiji ugotovljeno povprečno zmanjšanje po lestvici UPDRS za 0,13 točke glede na začetno vrednost 24,69 točke.
Azilect is used to treat Parkinson's disease. 
Zdravilo Azilect se uporablja za zdravljenje bolnikov s Parkinsonovo boleznijo.
This was compared with a rise of 4.07 points in the patients taking placebo from a starting value of 24.54. 
To so primerjali s povečanjem za 4,07 točke glede na začetno vrednost 24,54 točke pri bolnikih, ki so jemali placebo.
Why has Azilect been approved? 
Zakaj je bilo zdravilo Azilect odobreno?
Neurotransmitters are chemicals that nerve cells use to communicate with neighbouring cells. 
Živčni prenašalci so kemične snovi, ki omogočajo medsebojno sporazumevanje živčnih celic.
What is the risk associated with Azilect? 
Kakšna tveganja so povezana z zdravilom Azilect?
Azilect can be used either alone, or as an add-on to levodopa (another medicine used in Parkinson's disease) in patients who are having ‘fluctuations' towards the end of the period between levodopa doses. 
Zdravilo Azilect se lahko uporablja samostojno ali kot dodatek levodopi (drugemu zdravilu, ki se uporablja pri Parkinsonovi bolezni) pri bolnikih z nihanji proti koncu obdobja med dvema odmerkoma levodope.
Fluctuations are linked to a reduction in the effects of levodopa, when the patient experiences sudden switches between being ‘on' and able to move, and being ‘off' and immobile. 
Nihanja so povezana z zmanjšanim učinkom levodope, ko bolnik doživlja nenadne preskoke med stanjem, ko se lahko giblje (stanje „on“), in med stanjem, ko se ne more premikati (stanje „off“).
Azilect can only be obtained with a prescription. 
Izdaja zdravila je le na recept.
In both studies, patients adding Azilect spent an average of around one hour less in the ‘off' state than those adding placebo. 
V obeh študijah je bil pri bolnikih, ki so dodatno prejemali zdravilo Azilect, čas stanja „off“ v povprečju približno eno uro krajši kot pri bolnikih, ki so kot dodatek prejemali placebo.
Azilect must not be used with other monoamine oxidase inhibitors including medicines and herbal preparations obtained without prescription such as St John's wort. 
Zdravilo Azilect se ne sme uporabljati skupaj z drugimi zaviralci monoaminooksidaz, vključno z zdravili ali rastlinskimi pripravki, ki se dobijo brez recepta, kot je šentjanževka.
A similar decrease in time spent in the ‘off' state was seen in patients taking entacapone. 
Podobno skrajšanje časa, preživetega v stanju „off“ je bilo opaženo pri bolnikih, ki so prejemali entakapon.
There should be at least 14 days between stopping treatment with Azilect and starting treatment with another monoamine oxidase inhibitor or with pethidine. 
Med prenehanjem zdravljenja z zdravilom Azilect in začetkom zdravljenja z drugim zaviralcem monoaminooksidaz ali petidinom mora preteči najmanj 14 dni.
It must also not be used with pethidine (a painkiller). 
Ne sme se uporabljati skupaj s petidinom (zdravilom proti bolečinam).
By increasing levels of dopamine in the parts of the brain that control movement and co-ordination, Azilect improves the signs and symptoms of Parkinson's disease, such as stiffness and slowness of movement. 
Zdravilo Azilect s povečevanjem ravni dopamina v delih možganov, ki nadzorujejo gibe in koordinacijo, lajša znake in simptome Parkinsonove bolezni, kot sta okornost in počasnost gibov.
In the first study, two different doses of Azilect taken alone were compared with placebo (a dummy treatment) in 404 patients with early-stage disease. 
V prvi študiji so učinke dveh različnih odmerkov zdravila Azilect, dajanega samostojno, primerjali z učinki placeba (zdravila brez zdravilne učinkovine) pri 404 bolnikih z boleznijo v zgodnji fazi.
When used as an add-on to levodopa, 1 mg Azilect reduced the time in the ‘off' state more than placebo did. 
Zdravilo Azilect 1 mg, uporabljeno kot dodatek levodopi, je skrajšalo čas stanja „off“ bolj kot placebo.
In patients with Parkinson's disease, the cells that produce dopamine begin to die and the amount of dopamine in the brain decreases. 
Parkinsonovo boleznijo začnejo celice, ki proizvajajo dopamin, odmirati, zato se količina dopamina v možganih zmanjša.
For the full list of all side effects reported with Azilect, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Azilect, glejte navodilo za uporabo.
The active substance in Azilect, rasagiline, is a ‘monoamine oxidase-B inhibitor'. 
Zdravilna učinkovina zdravila Azilect je razagilin, zaviralec „monoaminooksidaze tipa B“.
How has Azilect been studied? 
Kako je bilo zdravilo Azilect raziskano?
What is Azilect used for? 
Za kaj se zdravilo Azilect uporablja?
How is Azilect used? 
Kako se zdravilo Azilect uporablja?
What is Azilect? 
Kaj je zdravilo Azilect?
How does Azilect work? 
Kako zdravilo Azilect deluje?
Further information on VeraSeal can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/veraseal 
Dodatne informacije o zdravilu VeraSeal so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/veraseal
VeraSeal received a marketing authorisation valid throughout the EU on 10 November 2017. 
Za zdravilo VeraSeal je bilo 10. novembra 2017 izdano dovoljenje za promet, veljavno po vsej EU.
What measures are being taken to ensure the safe and effective use of VeraSeal? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila VeraSeal?
VeraSeal is used when standard surgery techniques do not work well enough. 
Zdravilo VeraSeal se uporablja, kadar standardne kirurške tehnike niso dovolj učinkovite.
Other information about VeraSeal 
Druge informacije o zdravilu VeraSeal
The European Medicines Agency therefore decided that VeraSeal's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila VeraSeal večje od z njim povezanih tveganj, in priporočila, da se odobri za uporabo v EU.
Rarely, VeraSeal may cause an allergic reaction which can be severe especially when the medicine is used repeatedly. 
Redko lahko zdravilo VeraSeal povzroči alergijsko reakcijo, ki je lahko resna, zlasti ob večkratni uporabi zdravila.
As for all medicines, data on the use of VeraSeal are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila VeraSeal stalno spremljajo.
What benefits of VeraSeal have been shown in studies? 
Kakšne koristi zdravila VeraSeal so se pokazale v študijah?
Although patients could develop antibodies against the medicine, which might reduce its effectiveness, this has not been seen in the studies. 
Čeprav se pri bolnikih lahko pojavijo protitelesa proti zdravilu, kar lahko zmanjša njegovo učinkovitost, tega v študijah niso opazili.
What is VeraSeal and what is it used for? 
Kaj je zdravilo VeraSeal in za kaj se uporablja?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of VeraSeal have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila VeraSeal upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
An overview of VeraSeal and why it is authorised in the EU 
Pregled zdravila VeraSeal in zakaj je odobreno v EU
It is available as two prefilled syringes in a syringe holder, one containing a solution of human fibrinogen (80 mg/ml), and the other containing a solution of human thrombin (500 international units/ml). 
Na voljo je v dveh napolnjenih injekcijskih brizgah v držalu za injekcijske brizge, pri čemer ena brizga vsebuje raztopino s humanim fibrinogenom (80 mg/ml), druga pa raztopino s humanim trombinom (500 mednarodnih enot/ml).
VeraSeal (human fibrinogen / human thrombin) 
VeraSeal (humani fibrinogen/humani trombin)
As for all medicines obtained from blood, infections could be transmitted with the medicine; however, the medicine is manufactured using filtration and a process to inactivate viruses that minimise this risk. 
Kot velja za vsa zdravila, pridobljena iz krvi, se z zdravilom lahko prenašajo okužbe, vendar je to izdelano s filtracijo in postopkom inaktivacije virusov, kar to tveganje zmanjšuje.
Why is VeraSeal authorised in the EU? 
Zakaj je bilo zdravilo VeraSeal odobreno v EU?
VeraSeal should only be used by an experienced surgeon who has been trained in its use. 
Zdravilo VeraSeal sme uporabljati samo izkušeni kirurg, ki je bil usposobljen za njegovo uporabo.
The amount of VeraSeal to be used depends on a number of factors, including the type of surgery, the size of the wound and the number of applications. 
Količina zdravila VeraSeal, ki jo je treba uporabiti, je odvisna od številnih dejavnikov, vključno z vrsto kirurškega posega, velikostjo rane in številom nanosov.
The active substances in VeraSeal, fibrinogen and thrombin, are substances present in human plasma (the liquid part of the blood), which are involved in the normal blood clotting process. 
Učinkovini v zdravilu VeraSeal, fibrinogen in trombin, sta snovi, prisotni v človeški plazmi (tekočem delu krvi), ki sodelujeta pri običajnem strjevanju krvi.
What are the risks associated with VeraSeal? 
Kakšna tveganja so povezana z zdravilom VeraSeal?
Side effects reported with VeraSeal are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu VeraSeal, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
The observed side effects were as expected with major surgeries or the patient's condition. 
Opaženi neželeni učinki so bili takšni, kot se pričakujejo pri večjih kirurških posegih oziroma glede na bolnikovo stanje.
The most common side effects with VeraSeal (which may affect up to 1 in 10 people) are nausea (feeling sick), pruritus (itchiness) and procedural pain (pain from the surgery). 
Najpogostejši neželeni učinki zdravila VeraSeal (ki se lahko pojavijo pri največ 1 od 10 bolnikov) so navzeja (siljenje na bruhanje), pruritus (srbenje) in bolečina pri posegu (bolečina zaradi kirurškega posega).
VeraSeal has been shown to effectively stop bleeding during surgery, which can be expected to reduce blood loss, reduce time in the operating theatre and possibly shorten hospital stays. 
Dokazano je bilo, da zdravilo VeraSeal učinkovito ustavi krvavitev med kirurškim posegom, kar po pričakovanju zmanjša izgubo krvi, skrajša čas v operacijski dvorani in morda skrajša ležalno dobo.
When the two active substances are mixed, thrombin cuts fibrinogen up into fibrin. 
Ko se učinkovini zmešata, trombin razreže fibrinogen v fibrin.
VeraSeal must not be used intravascularly (inside blood vessels) or to treat heavy bleeding of the arteries. 
Zdravilo VeraSeal se ne sme uporabljati intravaskularno (znotraj žil) ali za zdravljenje obilnih krvavitev iz arterij.
In rare cases, patients have developed antibodies to the proteins in VeraSeal, which could interfere with blood clotting. 
V redkih primerih so se pri bolnikih pojavila protitelesa proti beljakovinam v zdravilu VeraSeal, ki lahko ovirajo strjevanje krvi.
It contains the active substances human fibrinogen and human thrombin. 
Vsebuje učinkovini humani fibrinogen in humani trombin.
Three main studies in 614 patients found that VeraSeal is effective at stopping bleeding within 4 minutes of applying it during surgery. 
V treh glavnih študijah pri 614 bolnikih so ugotovili, da je zdravilo VeraSeal med kirurškim posegom učinkovito pri ustavitvi krvavitve v štirih minutah po nanosu.
For the full list of all side effects and restrictions with VeraSeal, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila VeraSeal glejte navodilo za uporabo.
Before use, the syringes are attached to a device supplied with the medicine that allows their contents to mix as they are dripped or sprayed on the wound. 
Pred uporabo se injekcijski brizgi pritrdita na pripomoček, priložen zdravilu, ki omogoča, da se njuni vsebini zmešata med nanosom na rano s kapljanjem ali pršenjem.
How is VeraSeal used? 
Kako se zdravilo VeraSeal uporablja?
In a second study of organ surgery, VeraSeal was as effective as another product Surgicel: 93% of the patients had no bleeding 4 minutes after treatment with VeraSeal (103 out of 111), while 81% of the patients had no bleeding with Surgicel (91 out of 113). 
V drugi študiji pri kirurškem posegu na organih je bilo zdravilo VeraSeal enako učinkovito kot drugo zdravilo, zdravilo Surgicel: po štirih minutah ni več krvavelo 93 % (103 od 111) bolnikov , zdravljenih z zdravilom VeraSeal, in 81 % (91 od 113) bolnikov, zdravljenih z zdravilom Surgicel.
How does VeraSeal work? 
Kako zdravilo VeraSeal deluje?
In one study of blood vessel surgery, VeraSeal worked better than manual compression, with 76% of patients having no bleeding 4 minutes after treatment with VeraSeal (83 out of 109), compared with 23% after manual compression (13 out of 57). 
V študiji pri kirurškem posegu na žilah je zdravilo VeraSeal delovalo bolje kot ročna kompresija, pri čemer 76 % (83 od 109) bolnikov, zdravljenih z zdravilom VeraSeal, po štirih minutah ni več krvavelo, delež takšnih bolnikov, zdravljenih z ročno kompresijo, pa je bil 23 % (13 od 57 bolnikov).
Finally, in a third study of soft tissue surgery, VeraSeal was as effective as Surgicel: 83% of the patients had no bleeding 4 minutes after treatment with VeraSeal (96 out of 116), compared with 78% of the patients after treatment with Surgicel (84 out of 108). 
V tretji študiji pri kirurškem posegu na mehkih tkivih je bilo zdravilo VeraSeal enako učinkovito kot zdravilo Surgicel: po štirih minutah ni več krvavelo 83 % (96 od 116) bolnikov, zdravljenih z zdravilom VeraSeal, in 78 % (84 od 108) bolnikov, zdravljenih z zdravilom Surgicel.
VeraSeal is a sealant (glue) used to stop bleeding during surgery or to support stitches during surgery on blood vessels. 
Zdravilo VeraSeal je lepilo za tkiva, ki se uporablja za ustavitev krvavitve med kirurškim posegom ali kot opora šivom med kirurškim posegom na žilah.
Thromboembolic complications (blood clots) may occur if VeraSeal is accidentally injected into a blood vessel. 
Če se zdravilo VeraSeal nenamerno injicira v žilo, lahko nastanejo trombembolični zapleti (krvni strdki).
18 weeks. 
18 tednov.
MN HAI MN HAI MN HAI MN HAI 
Preiskovanci s 4-kratnim porastom protiteles (odstotek) MN HAI MN HAI MN HAI MN HAI
The safety and efficacy of the vaccine in this population has not been established. 
Varnost in učinkovitost tega cepiva v tej populaciji nista ugotovljeni.
Small white particles may be present. 
Vsebuje lahko majhne bele delce.
Age range as described in the protocol for the study. 
Razpon starosti, kot je opisan v protokolu študije.
Two doses are recommended for all children and adolescents. 
Za vse otroke in mladostnike sta priporočena dva odmerka.
See section 5 for advice on storage and disposal. 
Glejte 5. poglavje za nasvet o shranjevanju in odstranjevanju.
.......................................................................................................per 0.2 ml dose 
.......................................................................................................na 0,2-ml odmerek
It spreads rapidly around the world. 
Pandemska gripa se hitro širi po vsem svetu.
No deaths resulted from these events, and none of the hospitalised children required mechanical ventilation or admission to an intensive care unit. 
Smrti zaradi teh dogodkov ni bilo in noben otrok, sprejet v bolnišnico, ni potreboval mehanične ventilacije ali sprejema na oddelek za intenzivno nego.
Four placebo-controlled studies included second season revaccination. 
Štiri s placebom kontrolirane študije so vključevale ponovno cepljenje drugo sezono.
Adults aged 18 to 49 years 
Odrasli v starosti od 18 do 49 let
For signs of allergic reactions, see section 4 “Possible side effects”. 
Za znake alergijskih reakcij glejte poglavje 4, "Možni neželeni učinki".
The signs of pandemic flu are similar to those of ordinary flu but may be more serious. 
Njeni znaki so podobni znakom navadne gripe, a so lahko veliko resnejši.
• if you have a blood disorder or a cancer that affects the immune system. 
• če imate kakšno krvno bolezen ali raka, ki vpliva na imunski sistem.
None of the ingredients in the vaccine can cause the flu. 
Nobena od sestavin cepiva ne more povzročiti gripe.
Influenza season 
Sezona gripe
1 dose (0.2 ml) contains: 
1 odmerek (0,2 ml) vsebuje:
Read all of this leaflet carefully before the vaccine is given because it contains important information for you or your child. 
Pred uporabo cepiva natančno preberite navodilo, ker vsebuje za vas ali vašega otroka pomembne podatke!
• if you have been told by your doctor that you have a weakened immune system as a result of a disease, medicine, or other treatment. 
• če vam je zdravnik povedal, da imate oslabljen imunski sistem zaradi bolezni, zdravil ali kakšnega drugega zdravljenja.
This is because the vaccine may work less effectively. 
Cepivo je namreč lahko v tem primeru manj učinkovito.
• severe allergic reaction: signs of a severe allergic reaction may include shortness of breath and swelling of the face or tongue. 
• huda alergijska reakcija: med znaki hude alergijske reakcije so lahko težko dihanje in oteklost obraza ali jezika.
Adults aged 22 to 54 years 
Odrasli v starosti od 22 do 54 let
The second dose should be administered after an interval of at least 4 weeks. 
Drugi odmerek je treba dati po presledku vsaj 4 tednov.
No data are available for individuals with severe immunosuppression (see section 4.4). 
Podatkov za osebe s hudo imunosupresijo ni na voljo (glejte poglavje 4.4).
56 Days after inactivated vaccine 
56 dni po inaktiviranem cepivu
Africa, Latin America 
Afrika, Latinska Amerika
Serological response defined as a ≥4-fold rise in antibody titer (≥1:20). 
Serološki odziv je opredeljen kot ≥ 4-kratno povečanje titra protiteles (≥ 1:20).
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. 
Zaradi pomanjkanja študij kompatibilnosti se cepiva ne sme mešati z drugimi zdravili.
H1N1 pandemic LAIV vaccine in children aged 2 to 17 years 
Pandemsko cepivo LAIV H1N1 pri otrocih v starosti od 2 do 17 let
fewer cases than injectable fewer cases than injectable 
manj primerov kot z injiciranim manj primerov kot z injiciranim
• if you have severe asthma or are currently wheezing. 
• če imate hudo astmo ali trenutno piskajoče dihate.
At the time of approval of the next pandemic variation 
Ob času odobritve naslednje spremembe za pandemijo.
Pandemic flu is a type of influenza that happens at intervals that vary from less than 10 years to many decades. 
Pandemska gripa je vrsta gripe, ki se pojavlja v presledkih; ti presledki lahko trajajo od manj kot 10 let do nekaj desetletij.
Children less than 12 months of age should not receive this vaccine because of the risk of side effects. 
Otroci, mlajši od 12 mesecev, zaradi tveganja za neželene učinke ne smejo dobiti tega cepiva.
28 Days after inactivated vaccine 
28 dni po inaktiviranem cepivu
Therefore, as some viruses are excreted in human milk, the vaccine should not be used during breastfeeding. 
Ker se nekateri virusi pri človeku izločajo v materino mleko, se tega cepiva med nosečnostjo ne sme uporabljati.
The influenza strain used for the vaccine in an offically declared pandemic is recommended by the World Health Organisation. 
Sev gripe, uporabljen v cepivu med uradno razglašeno pandemijo, priporoča Svetovna zdravstvena organizacija.
This is because of the risk of a very rare but serious disease (Reye's syndrome). 
Vzrok za to je tveganje za zelo redko, vendar resno bolezen (Reyev sindrom).
T/LAIV efficacy 
Učinkovitost T/LAIV
Data presented for clinical trial D153-P504 are for study participants who received two doses of study vaccine or placebo. 
Podatki, prikazani za klinično preskušanje D153-P504, so podatki za tiste udeležence študije, ki so prejeli dva odmerka raziskovanega cepiva ali placeba.
This is because of the risk of Reye's syndrome, a very rare but serious disease that can affect the brain and liver. 
Vzrok za to je tveganje za Reyev sindrom: to je zelo redka, vendar resna bolezen, ki lahko prizadene možgane in jetra.
Date of first authorisation: 20 May 2016 Date of latest renewal: 4 April 2018 
Datum prve odobritve: 20. maj 2016
In accordance with Article 114 of Directive 2001/83/EC, the official batch release will be undertaken by a State laboratory or a laboratory designated for that purpose. 
V skladu s členom 114 Direktive 2001/83/ES z vsemi dopolnitvami in spremembami, serijo uradno sprosti državni laboratorij ali laboratorij, določen v ta namen.
The maximum amount of ovalbumin is less than 0.024 micrograms per 0.2 ml dose (0.12 micrograms per ml). 
Največja količina ovalbumina je manjša od 0,024 mikrograma na 0,2-ml odmerek (0,12 mikrograma na ml).
• if you are in close contact with someone with a severely weakened immune system (for example, a bone marrow transplant patient needing isolation). 
• če ste v tesnem stiku s kom, ki ima močno oslabel imunski sistem (npr. bolnik po presaditvi kostnega mozga, ki potrebuje izolacijo).
Geometric mean titer 
Geometrična sredina titra
• If you are pregnant, think you may be pregnant, or plan to become pregnant soon, tell your doctor, nurse or pharmacist before vaccination. 
• Če ste noseči, menite, da bi lahko bili noseči ali kmalu načrtujete zanositev, morate o tem pred cepljenjem obvestiti zdravnika, medicinsko sestro ali farmacevta.
Of these subjects, 319 received a second dose (256 subjects monovalent vaccine; 63 subjects placebo). 
Od teh preiskovancev jih je 319 prejelo drugi odmerek (256 monovalentno cepivo, 63 placebo).
6 to 59 M 7,852 2004-2005 
6 do 59 m 7.852 2004-2005
Immune response in patients with endogenous or iatrogenic immunosuppression may be insufficient. 
Imunski odziv je lahko nezadosten pri bolnikih z endogeno ali iatrogeno imunosupresijo.
• DO NOT USE WITH A NEEDLE. 
• NE UPORABLJAJTE GA Z IGLO.
It is used in children and adolescents 12 months to less than 18 years of age. 
Uporabljamo ga pri otrocih in mladostnikih v starosti od 12 mesecev do manj kot 18 let.
• if the child is less than 12 months of age. 
• če je otrok mlajši od 12 mesecev.
Liverpool L24 9JW United Kingdom 
Liverpool L24 9JW, Velika Britanija
In clinical studies with the vaccine, most side effects were mild in nature and short-term. 
V kliničnih študijah s tem cepivom je bila večina neželenih učinkov blagih in kratkotrajnih.
Subjects with 4-fold antibody rise (percentage) 
Preiskovanci s 4-kratnim porastom protiteles (odstotek)
When a person is given the vaccine, the immune system (the body's natural defence system) will produce its own protection against the influenza virus. 
Ko oseba dobi cepivo, imunski sistem (naravni obrambni sistem telesa) ustvari lastna protitelesa proti virusu gripe.
Days are counted relative to the only P/IIV dose for Groups 1-4 and after the first of 2 P/IIV doses for Group 5. 
Dnevi so šteti glede na edini odmerek P/IIV za 1. do 4. skupino in po prvem od dveh odmerkov P/IIV za 5. skupino.
- This vaccine has been prescribed for you or your child only. 
- Cepivo je bilo predpisano vam ali vašemu otroku osebno in ga ne smete dajati drugim.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements for medical waste. 
Neuporabljeno cepivo ali odpadni material zavrzite v skladu z lokalnimi predpisi za medicinske odpadke.
Other special populations: 
Druge posebne skupine bolnikov: